meta
|
COVID-19
Dynamic meta-analysis of evidences about drug efficacy and safety
adjuvant therapies
anti-inflammatoty and immuno-therapy
Immunosuppressants drugs
adalimumab
anakinra
anti-interleukin-6
clazakizumab
sarilumab
sarilumab azithromycin hydroxychloroquine
sarilumab high dose (400mg)
sarilumab low dose (200mg)
siltuximab
tocilizumab
baricitinib
baricitinib plus remdesivir
eculizumab
jakotinib
lenzilumab
ruxolitinib
tacrolimus
tetrandrine
antiandrogenic
antiviral and associated therapy
control
honey
miscellaneous
vaccines
potential COVID-19 treatments
control
placebo
standard of care
All
COVID-19
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 prophylaxis
infections other than COVID-19
preventing respiratory virus transmission
patient subgroup...
Studies
Meta-analysis
Excluded
Study
Exclusion reasons
Remarks
Reference(s)
Empty list - no studies excluded